{"success":true,"data":{"pressRelease":{"id":"129585","rtpr_id":"nGNX4dyrby","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","published_at":"2026-08-27T14:14:25.090Z","article_body":"LOS ANGELES, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e7qhTkax8PBPLLkNtgAFzqTRJruVz9mRDUHXCcONOJU18PuvLF8dXUcKM68ra-iA2IH0wtjyqJF5GC647Jl069bQUCsvhjHz3yd-Bb5-SyimiXBIm8cFFAbljXA0LLWO)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Regeneron Pharmaceuticals, Inc.\n(“Regeneron” or “the Company”) (NASDAQ: REGN\n(https://www.globenewswire.com/Tracker?data=hnIf5VfzOKQvXCzsut37PKdJ9Qjj495XVjAHOU9deGfR32hrIl7YiTnQyiLrX4tjuTs8biqj4rEEnTC_XpJjtGbTo4qzbhsTmB5suIdT5Nk=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of REGN during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: August 1, 2025 to May 15, 2026\n\nDEADLINE: September 14, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=gKs4m4lm7R-ZlWOGCjJ5Eqj4_BDz__Y0OhGmPqLaQ6QvhPeBtvDNGHqc-hcYmENPG4LP9PGV7zMf2BGy41bWUdR2Vg8iajEkzWegn2PBDOZGrkCmf607nhPAtJ7clnK5WC90z2YMj6XDTbLi5I-jY_wL5TAyqCWlZgogI1i0pSI=).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Regeneron led investors to believe that\nits Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its\nprimary endpoint. The Company utilized flawed statistical assumptions. In\nfact, the Company failed to demonstrate clinical differentiation from other\ntherapies. Based on these facts, the Company’s public statements were false\nand materially misleading throughout the class period. When the market learned\nthe truth about Regeneron, investors suffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=H3WnJa_qqBgEmESCZ5sSmqrujBPDWRBPDgGF8vXGVQvddsAZlbkjnZEqShh9XmESnRlQXwO3gUlKkAXXgrHRv54FJDhJfP8pbN7_6zDh6RA38PJtj_09dJY8mjW3Pklv1bqA5mdokhrTWWjWinCu0w==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4dyrby","title":"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","ticker":"REGN","created":"2026-08-27T14:14:25.090Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e7qhTkax8PBPLLkNtgAFzqTRJruVz9mRDUHXCcONOJU18PuvLF8dXUcKM68ra-iA2IH0wtjyqJF5GC647Jl069bQUCsvhjHz3yd-Bb5-SyimiXBIm8cFFAbljXA0LLWO)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Regeneron Pharmaceuticals, Inc.\n(“Regeneron” or “the Company”) (NASDAQ: REGN\n(https://www.globenewswire.com/Tracker?data=hnIf5VfzOKQvXCzsut37PKdJ9Qjj495XVjAHOU9deGfR32hrIl7YiTnQyiLrX4tjuTs8biqj4rEEnTC_XpJjtGbTo4qzbhsTmB5suIdT5Nk=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of REGN during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: August 1, 2025 to May 15, 2026\n\nDEADLINE: September 14, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=gKs4m4lm7R-ZlWOGCjJ5Eqj4_BDz__Y0OhGmPqLaQ6QvhPeBtvDNGHqc-hcYmENPG4LP9PGV7zMf2BGy41bWUdR2Vg8iajEkzWegn2PBDOZGrkCmf607nhPAtJ7clnK5WC90z2YMj6XDTbLi5I-jY_wL5TAyqCWlZgogI1i0pSI=).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Regeneron led investors to believe that\nits Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its\nprimary endpoint. The Company utilized flawed statistical assumptions. In\nfact, the Company failed to demonstrate clinical differentiation from other\ntherapies. Based on these facts, the Company’s public statements were false\nand materially misleading throughout the class period. When the market learned\nthe truth about Regeneron, investors suffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=H3WnJa_qqBgEmESCZ5sSmqrujBPDWRBPDgGF8vXGVQvddsAZlbkjnZEqShh9XmESnRlQXwO3gUlKkAXXgrHRv54FJDhJfP8pbN7_6zDh6RA38PJtj_09dJY8mjW3Pklv1bqA5mdokhrTWWjWinCu0w==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-27T14:14:25.132968462Z","server_sent_at_ms":1787840065132},"received_at":"2026-08-27T14:14:25.183Z","source_url":null},"analysis":{"id":"118499","press_release_id":"129585","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice naming Regeneron Pharmaceuticals; no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm regarding alleged securities fraud linked to a Phase III study.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Brian Schall","role":"Attorney/Partner"},{"name":"Andrew Brown","role":"Attorney/Partner"},{"name":"David Schwartz","role":"Attorney/Partner"}],"products":["Fianlimab-Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Schall, Brown & Schwartz LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"REGN"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice naming Regeneron Pharmaceuticals; no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm regarding alleged securities fraud linked to a Phase III study.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Brian Schall","role":"Attorney/Partner"},{"name":"Andrew Brown","role":"Attorney/Partner"},{"name":"David Schwartz","role":"Attorney/Partner"}],"products":["Fianlimab-Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T16:10:41.081Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":87054,"modelName":"glm-4.7"}}